Buprenorphine and Fosnetupitant: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Buprenorphine
Fosnetupitant
No brand names on record
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Here's what's going on. Your body uses an enzyme called CYP3A4 to break down buprenorphine, your pain or opioid-treatment medicine. Fosnetupitant (an anti-nausea drug often given with chemotherapy) can slow that enzyme down. When it does, buprenorphine clears out more slowly and can build up in your blood.
More buprenorphine can mean stronger opioid effects, like extra drowsiness, slowed breathing, or feeling overly sedated. The good news is this is very manageable. Your care team can adjust your buprenorphine dose and watch you a little more closely while you take both. Please don't change anything on your own, just check in with your pharmacist or doctor.
Mechanism: Fosnetupitant (via its active moiety netupitant, a moderate CYP3A4 inhibitor) inhibits CYP3A4-mediated metabolism of buprenorphine, increasing buprenorphine exposure (AUC/Cmax). Neither agent's relevant effect here depends on prodrug activation for this direction.
Effect: Elevated plasma buprenorphine, risk of prolonged opioid effects including sedation and respiratory depression.
Evidence: Probable; severity major; onset unspecified.
Management:
- Monitor closely for sedation and respiratory depression.
- Buprenorphine dose may need reduction until stable effects achieved.
- On inhibitor discontinuation, watch for withdrawal and consider dose increase.
- Consider a formulation allowing precise titration if needed.
What happens
Increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events
Interaction Deep Dive
Coadministration of buprenorphine with a CYP3A4 inhibitor can raise buprenorphine plasma concentrations, potentially producing extended opioid effects such as respiratory depression. When a patient on buprenorphine requires a CYP3A4 inhibitor, one option is to lower the buprenorphine dose until stable drug effects are reached, with frequent monitoring for sedation and respiratory depression. Conversely, if a CYP3A4 inhibitor is stopped in someone receiving buprenorphine, an increase in the buprenorphine dose may be warranted until stable effects are established, watching for indications of opioid withdrawal2. Should the dose prove impossible to adjust once the CYP3A4 inhibitor is gone, the patient should be switched back to a buprenorphine formulation that allows finer dose titration. For patients moving from transmucosal buprenorphine given together with CYP3A4 inhibitors, confirm through monitoring that the plasma buprenorphine level delivered by subQ buprenorphine is sufficient. For those already receiving subQ buprenorphine who then need a CYP3A4 inhibitor, watch for signs and symptoms of over-medication. Should indications of buprenorphine toxicity or overdose appear while the accompanying medication can neither be reduced nor stopped, decrease the buprenorphine dose. When the available doses cannot deliver the target dose, stop treatment and manage the patient using a buprenorphine formulation that permits more precise dose adjustments 1.
Why it happens (mechanism)
Inhibition of CYP3A4-mediated metabolism of buprenorphine
How to manage this interaction
The key point: keep taking both medicines exactly as prescribed unless your care team tells you otherwise. This combination is manageable with the right adjustments.
Here's what your team may do:
- Consider lowering your buprenorphine dose until your response is stable, and monitor you more closely for sedation or slowed breathing.
- When the fosnetupitant is stopped, they may raise your buprenorphine dose again and watch for withdrawal signs.
- Possibly switch to a buprenorphine formulation that allows finer dose adjustments.
Call your pharmacist or prescriber right away if you notice unusual drowsiness, confusion, or slow or shallow breathing.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
1 report — tap to read
a) The impact of concurrently administered CYP3A4 inhibitors on buprenorphine levels in patients receiving subQ buprenorphine has not been investigated; nevertheless, these interactions have been documented in studies employing transmucosal buprenorphine. The effects of buprenorphine may vary according to the route of administration 1.
Common questions
Can I take Buprenorphine and Fosnetupitant together?
Fosnetupitant can raise buprenorphine levels and increase opioid effects like sedation and slowed breathing, so your care team may lower your buprenorphine dose and monitor you more closely. Keep taking both as prescribed and report any excessive drowsiness or breathing changes. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Buprenorphine and Fosnetupitant interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Buprenorphine and Fosnetupitant interaction managed?
The key point: keep taking both medicines exactly as prescribed unless your care team tells you otherwise. This combination is manageable with the right adjustments. Here's what your team may do: Consider lowering your buprenorphine dose until your response is stable, and monitor you more closely for sedation or slowed breathing. When the fosnetupitant is stopped, they may raise your buprenorphine… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Questions for your pharmacist
- Does my dose of Buprenorphine or Fosnetupitant need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (2)
- Product Information: BRIXADI(TM) subcutaneous extended-release injection, buprenorphine subcutaneous extended-release injection. Braeburn Inc (per FDA), Plymouth Meeting, PA, 2023. DailyMed
- Product Information: ZUBSOLV(R) sublingual tablets, buprenorphine naloxone sublingual tablets. Orexo US Inc (per FDA), Morristown, NJ, 2023. DailyMed
Keep reading about Buprenorphine
Keep reading about Fosnetupitant
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist